Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40NG9 | ISIN: US83548R4020 | Ticker-Symbol: H3D0
NASDAQ
06.06.25 | 21:48
1,230 US-Dollar
+6,96 % +0,080
1-Jahres-Chart
SONNET BIOTHERAPEUTICS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
SONNET BIOTHERAPEUTICS HOLDINGS INC 5-Tage-Chart

Aktuelle News zur SONNET BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoSonnet Biotherapeutics erhält Delisting-Mitteilung von der NASDAQ3
MoSonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report-
13.05.Sonnet BioTherapeutics Holdings, Inc. - 10-Q, Quarterly Report4
SONNET BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
01.05.Sonnet BioTherapeutics Holdings, Inc.: Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit2
16.04.Sonnet BioTherapeutics Holdings, Inc.: Sonnet Releases Virtual Investor "What This Means" Segment4
04.04.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report5
04.04.Sonnet BioTherapeutics Holdings, Inc.: Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest ...232Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq®) The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg in combination...
► Artikel lesen
01.04.Sonnet BioTherapeutics Holdings, Inc.: Sonnet Announces Release of Corporate Update Video3
01.04.Sonnet BioTherapeutics ernennt Interims-CEO nach dem Tod des Gründers2
01.04.Sonnet BioTherapeutics appoints interim CEO after founder's death3
01.04.Sonnet BioTherapeutics Holdings, Inc.: Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.158PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted...
► Artikel lesen
26.03.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report2
26.03.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas191SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy...
► Artikel lesen
19.03.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report3
19.03.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant ...189Company advancing development of its modified version of Interleukin-18 (IL-18Binding Protein Resistant or IL-18BPR) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable...
► Artikel lesen
26.02.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors4
26.02.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report1
19.02.Sonnet BioTherapeutics advances novel ADC platform1
19.02.Sonnet BioTherapeutics macht Fortschritte bei neuartiger ADC-Plattform1
19.02.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline ...114Building on proven targeting of the FHAB domain, Sonnet's ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR) An epidermal growth factor receptor 2 (HER2) ADC...
► Artikel lesen
Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1